Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework - Bischof, GN; Dodich, A; Boccardi, M (Eur J Nucl Med Mol Imaging, 2021)
et al.